

Julia Spierings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3614865/publications.pdf>

Version: 2024-02-01

53
papers

386
citations

933447

10
h-index

839539

18
g-index

54
all docs

54
docs citations

54
times ranked

573
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical Therapy in Systemic Sclerosis: The Patient Perspective. <i>Arthritis Care and Research</i> , 2023, 75, 145-151.	3.4	2
2	Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1476-1486.	1.9	7
3	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1948-1956.	1.9	6
4	Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 239719832110433.	1.7	1
5	Capillaroscopy of the Nailfold in patients with Peripheral Artery Disease of the Lower Limb (CAPAD) Tj ETQq1 1 0.784314 rgBJ /Overl	1.5	2
6	Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features. <i>Journal of Rheumatology</i> , 2022, 49, 544-546.	2.0	1
7	Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 96-101.	1.7	1
8	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110351.	2.7	8
9	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	1.9	11
10	Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. <i>Rheumatology</i> , 2021, 60, e326-e328.	1.9	2
11	Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-associated Pulmonary Hypertension. <i>Arthritis and Rheumatology</i> , 2021, 73, 725-727.	5.6	1
12	P151 Self-assessment of scleroderma skin thickness: development and evaluation of the PASTUL questionnaire. <i>Rheumatology</i> , 2021, 60, .	1.9	0
13	POS1419 PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 993.1-993.	0.9	0
14	AB0914 INFORMATION PREFERENCES ABOUT TREATMENT OPTIONS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A DELPHI CONSENSUS STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1478.3-1479.	0.9	0
15	POS0249 THE EFFECT OF NASAL STAPHYLOCOCCUS AUREUS COLONIZATION ON DISEASE ACTIVITY AND THE EFFECT OF ANTIBIOTIC TREATMENT IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS; A RETROSPECTIVE COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 346-347.	0.9	0
16	AB0402 SELF-ASSESSMENT OF SCLERODERMA SKIN THICKNESS: DEVELOPMENT AND VALIDATION OF THE PASTUL QUESTIONNAIRE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1229.2-1230.	0.9	0
17	Physical therapy in patients with systemic sclerosis: physical therapists' perspectives on current delivery and educational needs. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	1.1	2
18	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. <i>Respiratory Medicine</i> , 2021, 187, 106579.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 199-205.	1.7	4
20	PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 819-820.	0.9	4
21	Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. <i>Rheumatology International</i> , 2021, 41, 1299-1310.	3.0	2
22	Living with systemic sclerosis: exploring its impact on caregivers. <i>Disability and Rehabilitation</i> , 2020, 42, 1632-1633.	1.8	3
23	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. <i>Rheumatology</i> , 2020, 59, 1226-1232.	1.9	11
24	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	1.9	13
25	Choosing a treatment: how can patients be guided through the labyrinth?. <i>Lancet Rheumatology</i> , The, 2020, 2, e130-e131.	3.9	1
26	Room for improvement in non-pharmacological systemic sclerosis care? – a cross-sectional online survey of 650 patients. <i>BMC Rheumatology</i> , 2020, 4, 43.	1.6	7
27	From "being at war" to "getting back on your feet": A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 202-209.	1.7	2
28	Cutibacterium acnes and autoinflammatory bone disease: Case series of three patients. <i>Clinical Immunology</i> , 2020, 219, 108540.	3.2	0
29	P5...Recognizing the disease, treating the patient: a mixed-method evaluation of care for the antiphospholipid syndrome (APS) in the Netherlands. , 2020, , .		0
30	Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa021.	0.7	2
31	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.9	32
32	The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. <i>Clinical and Experimental Immunology</i> , 2020, 201, 34-39.	2.6	9
33	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. <i>Clinical Immunology</i> , 2020, 214, 108392.	3.2	13
34	E070 Shared decision-making in progressive diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2019, 58, .	1.9	3
35	Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 399-416.	1.9	6
36	Second autologous haematopoietic stem cell transplantation in systemic sclerosis – a case report. <i>Rheumatology</i> , 2019, 58, 1305-1307.	1.9	2

#	ARTICLE	IF	CITATIONS
37	SAT0259â€¦...PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
38	AB0650â€¦...PERSPECTIVES AND UNMET NEEDS OF PATIENTS WITH POOR PROGNOSIS SYSTEMIC SCLEROSIS ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION CARE: A QUALITATIVE STUDY. , 2019, , .		0
39	OP0079â€¦...HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
40	AB1220â€¦...DISTRIBUTION OF RHEUMATOLOGISTS AND YOUNG RHEUMATOLOGISTSâ€™ ORGANIZATIONS ACROSS THE WORLD: STILL ROOM FOR IMPROVEMENT. , 2019, , .		0
41	PARE0019â€¦...LIVING WITH SYSTEMIC SCLEROSIS: EXPLORING ITS IMPACT ON CAREGIVERS: A QUALITATIVE STUDY. , 2019, , .		0
42	Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference. <i>Clinical Rheumatology</i> , 2019, 38, 1007-1015.	2.2	16
43	Diagnosing and treating antiphospholipid syndrome: a consensus paper. <i>Netherlands Journal of Medicine</i> , 2019, 77, 98-108.	0.5	15
44	A case of regional migratory osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 507-510.	3.1	2
45	Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?. <i>Immunology Letters</i> , 2018, 195, 88-96.	2.5	12
46	Hematopoietic stem-cell transplantation in systemic sclerosis: an update. <i>Current Opinion in Rheumatology</i> , 2018, 30, 541-547.	4.3	14
47	Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update. <i>Frontiers in Immunology</i> , 2018, 9, 767.	4.8	13
48	THU0655â€¦...Patientsâ€™ evaluation of dutch health care in systemic sclerosis: unmet needs and preferences. , 2018, , .		0
49	Heat shock proteins and their immunomodulatory role in inflammatory arthritis. <i>Rheumatology</i> , 2017, 56, 198-208.	1.9	36
50	Nodular Scleroderma. <i>Arthritis and Rheumatology</i> , 2015, 67, 3157-3157.	5.6	3
51	Antenatal ureaplasma infection impairs development of the fetal ovine gut in an IL-1-dependent manner. <i>Mucosal Immunology</i> , 2013, 6, 547-556.	6.0	48
52	IL-1 β Mediated Chorioamnionitis Induces Depletion of FoxP3+ Cells and Ileal Inflammation in the Ovine Fetal Gut. <i>PLoS ONE</i> , 2011, 6, e18355.	2.5	48
53	Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0